Skip to main content

Articles

Page 6 of 10

  1. Medicines use related challenges such as inadequate adherence, high levels of antimicrobial resistance and preventable adverse drug reactions have underscored the need to incorporate pharmaceutical services to...

    Authors: Niranjan Konduri, Megan Rauscher, Shiou-Chu Judy Wang and Tanya Malpica-Llanos

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:16

    Content type: Research

    Published on:

  2. The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in ...

    Authors: Alexander Freeman, Anthony Kwarteng, Lawrence Gyabaa Febir, Seeba Amenga-Etego, Seth Owusu-Agyei and Kwaku Poku Asante

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:15

    Content type: Research

    Published on:

  3. The purpose of this study is to explore medication-related perceptions of adult patients with type 2 diabetes attending treatment in public hospitals of urban centers in central Ethiopia.

    Authors: Bruck Messele Habte, Tedla Kebede, Teferi Gedif Fenta and Heather Boon

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:14

    Content type: Research

    Published on:

  4. The inappropriate use of antimicrobials is a problem worldwide. To target future interventions, a thorough understanding of the reasons behind this current behaviour is needed. Within the EU, the culture of an...

    Authors: Susanne Kaae, Admir Malaj and Iris Hoxha

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:13

    Content type: Research

    Published on:

  5. This article aims to highlight the positions of the Food and Drug Administration and the European Medicines Agency regarding use and marketing of hydroxyethyl starch (HES) products, and how these have changed ...

    Authors: Christian J. Wiedermann and Klaus Eisendle

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:12

    Content type: Policy analysis

    Published on:

  6. It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently,...

    Authors: Gereltuya Dorj, Bruce Sunderland, Tsetsegmaa Sanjjav, Gantuya Dorj and Byambatsogt Gendenragchaa

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:11

    Content type: Policy Analysis

    Published on:

  7. When patients are told that standard medical treatment options have been exhausted, their treating physicians may start looking for promising new drugs that are not yet approved, and still under investigation....

    Authors: Eline M. Bunnik, Nikkie Aarts and Suzanne van de Vathorst

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:10

    Content type: Commentary

    Published on:

  8. Lack of regulatory capacity limits the conduct of ethical and rigorous trials of herbal medicines in developing countries. Sharing ethical and regulatory experiences of successful herbal trials may accelerate ...

    Authors: Tsitsi G. Monera-Penduka, Charles C. Maponga, Gene D. Morse and Charles F. B. Nhachi

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:9

    Content type: Research

    Published on:

  9. Asthma as a chronic health condition can be controlled when in addition to clinical care, adequate education and support is provided to enhance self-management. Like many other chronic health conditions improv...

    Authors: Philip O. Anum, Berko P. Anto and Audrey G. Forson

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:8

    Content type: Research

    Published on:

  10. Private-sector retail drug outlets are often the first point of contact for common health ailments, including tuberculosis (TB). Systematic reviews on public-private mix (PPM) interventions for TB did not perf...

    Authors: Niranjan Konduri, Emily Delmotte and Edmund Rutta

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:6

    Content type: Research

    Published on:

  12. The Medicines Transparency Alliance (MeTA) is an initiative that brings together all stakeholders in the medicines market to create a multi-stakeholder dialogue and improve access, availability and affordabili...

    Authors: Gemma L. Buckland-Merrett, Catherine Kilkenny and Tim Reed

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:5

    Content type: Research

    Published on:

  13. The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focus...

    Authors: Rumiko Shimazawa and Masayuki Ikeda

    Citation: Journal of Pharmaceutical Policy and Practice 2017 10:4

    Content type: Research

    Published on:

  14. This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r)...

    Authors: Jörg Mahlich, Mona Groß, Alexander Kuhlmann, Johannes Bogner, Hans Heiken and Matthias Stoll

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:39

    Content type: Research

    Published on:

  15. There is substantial evidence of poor dispensing practices with inadequate packaging and labelling of medicines, and limited advice on their usage in low and middle-income countries (LMICs). We examined the la...

    Authors: N. Athuraliya, E. J. Walkom, S. Dharmaratne and J. Robertson

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:38

    Content type: Research

    Published on:

  16. It has been proven that the interaction between pharmaceutical representatives and physicians can directly influence the latter’s prescribing behaviour. This meta-synthesis aims to explore the available studie...

    Authors: Shahrzad Salmasi, Long Chiau Ming and Tahir Mehmood Khan

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:37

    Content type: Review

    Published on:

  17. The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation o...

    Authors: Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé, Corinne Pouget, Brigitte Renchon, Jean Rigal, Benedetta Schiavetti and Jean-Michel Caudron

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:36

    Content type: Commentary

    Published on:

  18. High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated...

    Authors: Akihiro Tanaka, Akiko Yano, Shinichi Watanabe, Mamoru Tanaka and Hiroaki Araki

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:35

    Content type: Short Report

    Published on:

  19. The increasing threat of antimicrobial resistance combined with the paucity of new classes of antibiotics represents a serious public health challenge. New treatment technologies could, in theory, have a signi...

    Authors: Ejike Nwokoro, Ross Leach, Christine Årdal, Enrico Baraldi, Kellie Ryan and Jens Plahte

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:34

    Content type: Research

    Published on:

  21. Annual immunization is the most effective way to prevent influenza and its associated complications. However, optimal immunization rates are not being met in Nova Scotia, Canada. Additional providers, such as ...

    Authors: Jennifer E. Isenor, Jessica L. Killen, Beverly A. Billard, Shelly A. McNeil, Donna MacDougall, Beth A. Halperin, Kathryn L. Slayter and Susan K. Bowles

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:32

    Content type: Research

    Published on:

  22. The emergence and spread of antibiotic resistant pathogens poses a big challenge to policy-makers, who need to oversee the transformation of health systems that evolved to provide easy access to these drugs in...

    Authors: Gemma L. Buckland Merrett, Gerald Bloom, Annie Wilkinson and Hayley MacGregor

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:31

    Content type: Review

    Published on:

  23. Many areas of pharmaceutical legislation in the European Union (EU) are harmonised in order to promote the internal market and protect public health. Ideally, harmonisation leads to less fragmented regulation ...

    Authors: Rasmus Borup, Susanne Kaae, Timo Minssen and Janine Traulsen

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:30

    Content type: Research

    Published on:

  24. The rising demand for chronic disease treatment and the barriers to accessing these medicines have led to the development of novel models for distributing medicines in South Africa’s public sector, including d...

    Authors: Bvudzai Priscilla Magadzire, Bruno Marchal and Kim Ward

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:28

    Content type: Research

    Published on:

  25. Worldwide the demands on emergency and primary health care services are increasing. General practitioners and accident and emergency departments are often used unnecessarily for the treatment of minor ailments...

    Authors: Louise E. Curley, Janice Moody, Rukshar Gobarani, Trudi Aspden, Maree Jensen, Maureen McDonald, John Shaw and Janie Sheridan

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:29

    Content type: Review

    Published on:

  26. Medicines are a main therapeutic intervention provided within hospitals and their proper use in the outpatient setting is important for patients and the community. The objective of this study was to evaluate d...

    Authors: Muhammad Atif, Muhammad Rehan Sarwar, Muhammad Azeem, Danial Umer, Abdul Rauf, Arslan Rasool, Muhammad Ahsan and Shane Scahill

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:27

    Content type: Research

    Published on:

  27. The United States (U.S.) Food and Drug Administration, as protectors of public health, encourages generic drug development and use so that patients can access affordable medications. The FDA, however, has limi...

    Authors: Chia-Ying Lee, Xiaohan Chen, Robert J. Romanelli and Jodi B. Segal

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:26

    Content type: Review

    Published on:

  28. The proposed Pharmacy Bill of Malaysia which served to consolidate and harmonise the existing pharmacy legislation which has been used for more than 60 years. This new Pharmacy Bill contains 17 parts and a tot...

    Authors: Kah Seng Lee, Yen Wei Lim and Long Chiau Ming

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:25

    Content type: Commentary

    Published on:

  29. Providing patient-centred care requires pharmacy students to learn how to interact effectively and understand individual differences that can influence patients’ health. The School of Pharmacy at The University o...

    Authors: Louise E. Curley, Maureen McDonald and Trudi Aspden

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:24

    Content type: Research

    Published on:

  31. Lack of access to insulin and poor health outcomes are issues for both low and high income countries. This has been accompanied by a shift from relatively inexpensive human insulin to its more expensive analog...

    Authors: Warren A. Kaplan and Reed F. Beall

    Citation: Journal of Pharmaceutical Policy and Practice 2016 10:3

    Content type: Research

    Published on:

  32. Pharmacists in Japan currently play a key role in patient hospital care. Their responsibilities include filling prescriptions, checking a patient’s medication history, and providing appropriate information to ...

    Authors: Daiki Yasunaga, Yuichi Tasaka, Satoshi Murakami, Akihiro Tanaka, Mamoru Tanaka and Hiroaki Araki

    Citation: Journal of Pharmaceutical Policy and Practice 2016 10:2

    Content type: Research

    Published on:

  33. Due to the lack of clear, comprehensive, and rational drug policy, the production of pharmaceutical preparations in India is distorted for the most part. Indian markets are flooded with more than 70,000 formul...

    Authors: Anandhasayanam Aravamuthan, Mohanavalli Arputhavanan, Kannan Subramaniam and Sam Johnson Udaya Chander J

    Citation: Journal of Pharmaceutical Policy and Practice 2016 10:1

    Content type: Research

    Published on:

  34. The Integrated Management of Childhood Illnesses is the main approach for treating children in more than 100 low income countries worldwide. In 2007, the World Health Assembly urged countries to integrate ‘bet...

    Authors: Xavier Nsabagasani, Japer Ogwal-Okeng, Ebba Holme Hansen, Anthony Mbonye, Herbert Muyinda and Freddie Ssengooba

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:22

    Content type: Research

    Published on:

  35. Uganda introduced a multipronged intervention, the supervision, performance assessment, and recognition strategy (SPARS), to improve medicines management (MM) in public and not-for-profit health facilities. Th...

    Authors: Birna Trap, Denis Okidi Ladwar, Martin Olowo Oteba, Martha Embrey, Mohammed Khalid and Anita Katharina Wagner

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:21

    Content type: Research

    Published on:

  36. In 2014, a qualitative multi-country research project was launched to study the reasons behind the high use of antibiotics in regions of Southeast Europe by using previously untrained national interviewers (wh...

    Authors: Susanne Kaae, Sofia Kälvemark Sporrong, Janine Morgall Traulsen, Helle Wallach Kildemoes, Lotte Stig Nørgaard, Arianit Jakupi, Denis Raka, Emre Umut Gürpinar, Ali Alkan, Iris Hoxha, Admir Malaj and Lourdes Arevalo Cantarero

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:20

    Content type: Research

    Published on:

  37. This editorial introduces a series of case studies that together highlight the use of health market interventions to improve access to medicines in low-and-middle income countries (LMICs). It underscores the a...

    Authors: Zubin Shroff, Maryam Bigdeli, Zaheer-Ud-Din Babar, Anita Wagner, Abdul Ghaffar and David H Peters

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:19

    Content type: Editorial

    Published on:

  38. Since its inception, the Uganda National Drug Authority (NDA) has regularly inspected private sector pharmacies to monitor adherence to Good Pharmacy Practices (GPP). This study reports findings from the first...

    Authors: Birna Trap, Kate Kikule, Catherine Vialle-Valentin, Richard Musoke, Grace Otto Lajul, Kim Hoppenworth and Dorthe Konradsen

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:18

    Content type: Research

    Published on:

  39. India shoulders the greatest global burden of cardiovascular diseases (CVDs), which are the leading cause of mortality worldwide. Drugs are the bedrock of treatment and prevention of CVD. India’s pharmaceutica...

    Authors: Charles Newman, Vamadevan S. Ajay, Ravi Srinivas, Sandeep Bhalla, Dorairaj Prabhakaran and Amitava Banerjee

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:16

    Content type: Research

    Published on:

  40. Exorbitant price increases for critical off-patent medicines have received considerable media attention in recent months, leading to an investigation by the U.S. Senate. However, much of this attention has foc...

    Authors: Adam R. Houston, Reed F. Beall and Amir Attaran

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:15

    Content type: Letter to the Editor

    Published on:

  41. Consumers are hesitant in choosing generic medications as they are under the assumption that they are not as safe nor effective as brand medications. However, pharmacists do have the education and training to ...

    Authors: Mira Patel, Marion Slack, Janet Cooley and Sandipan Bhattacharjee

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:17

    Content type: Research

    Published on:

  42. Achieving increased access to medicines in low- and middle-income countries is a complex issue that requires a holistic approach. Choosing an appropriate manufacturing strategy that can ensure a sustainable su...

    Authors: Mutsumi Metzler and Patricia S. Coffey

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:14

    Content type: Commentary

    Published on:

  43. Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical industry often make claims of delayed or lack of access to new cancer medicines—claims that ar...

    Authors: Agnes Vitry, Barbara Mintzes and Wendy Lipworth

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:13

    Content type: Commentary

    Published on:

  44. Many patients even those with health insurance pay out-of-pocket for medicines. We investigated the availability and prices of essential medicines in the Boston area.

    Authors: Abhishek Sharma, Lindsey Rorden, Margaret Ewen and Richard Laing

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:12

    Content type: Research

    Published on:

  45. A wide range of pharmaceutical products are needed for diagnosis, treatment, and prevention of HIV/AIDS. However, interrupted supplies and stock-outs are the major challenges in the supply chain of ARV medicin...

    Authors: Eyerusalem Berhanemeskel, Gebremedhin Beedemariam and Teferi Gedif Fenta

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:11

    Content type: Research

    Published on:

  46. Antibiotic resistance is a serious global public health problem directly correlated to high antibiotic consumption. Romania is one of the European countries with the highest rates of antibiotic consumption, no...

    Authors: I. Ghiga and C. Stålsby Lundborg

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:10

    Content type: Research

    Published on:

  47. In October 2015, the third international Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference was held in Vienna to foster discussion on challenges in pricing and reimbursement policies for m...

    Authors: Sabine Vogler, Nina Zimmermann, Alessandra Ferrario, Veronika J. Wirtz, Kees de Joncheere, Hanne Bak Pedersen, Guillaume Dedet, Valérie Paris, Aukje K. Mantel-Teeuwisse and Zaheer-Ud-Din Babar

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:9

    Content type: Editorial

    Published on:

  48. Financial recession mandated the introduction of harsh austerity measures. Health, and particularly pharmaceuticals, constitute a significant part of public expenditure and as such they have been subject to si...

    Authors: Panagiotis Petrou and Michael A. Talias

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:8

    Content type: Research

    Published on:

  49. Clinical pharmacy service has evolved steadily over the past few decades and is contributing to the ‘patient care journey’ at all stages. The service improves safety and effectiveness of medicines, thereby avo...

    Authors: Arebu Issa Bilal, Zelalem Tilahun, Gebremedhin Beedemariam, Belete Ayalneh, Bisrat Hailemeskel and Ephrem Engidawork

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:7

    Content type: Research

    Published on:

  50. Ghana established its National Health Insurance Scheme (NHIS) in 2003 with the goal of ensuring more equitable financing of health care to improve access to health services. This qualitative study examines the...

    Authors: Paul G. Ashigbie, Devine Azameti and Veronika J. Wirtz

    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:6

    Content type: Research

    Published on:

Submit manuscript

Follow

Annual Journal Metrics

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us